Raphael Borie | Gene Regulation Epigenetics | Best Researcher Award

Posted on by sciencefather

Prof. Dr. Raphael Borie | Gene Regulation Epigenetics | Best Researcher Award

Prof. Dr. Raphael Borie, APHP, France

Dr. Raphaël Borie, born on August 15, 1977, in Paris, France, is a leading expert in pulmonology and genetic respiratory diseases. Currently a University Professor Hospital Practitioner at Bichat Hospital (Paris Cité University), he has consistently contributed to the advancement of respiratory medicine, particularly in the field of interstitial lung diseases (ILDs). His clinical insight, combined with a strong research portfolio, has positioned him as a prominent figure within the OrphaLung network. A dedicated family man with two children, Dr. Borie is widely respected for his integrity, leadership, and commitment to collaborative medicine. His career reflects a unique blend of academic excellence and impactful translational research, bridging the gap between genomics and clinical care in ILD. He is a registered member of the French Medical Council (Ordre des Médecins No. 75/71138), and his research has influenced European clinical guidelines and improved the understanding of rare genetic pulmonary conditions.

Publication Profile: 

Scopus

✅ Strengths for the Award:

  1. Robust Academic Background:
    Dr. Borie holds a PhD in Genetics, Master’s in Physiology, and HDR (habilitation to supervise doctoral research), which underlines his scientific credibility and ability to lead independent research.

  2. Clinical-Research Integration:
    As a University Professor and Hospital Practitioner, he merges frontline patient care with cutting-edge genetic and respiratory disease research.

  3. High Publication Impact:
    With 283 PubMed-indexed articles and an H-index of 60, Dr. Borie’s work demonstrates strong citation influence, indicating widespread recognition and utility in the scientific community.

  4. International Leadership:
    Active in multinational collaborations (e.g., OrphaLung, ERS), he has co-authored major position statements and clinical trials, influencing European respiratory care guidelines.

  5. Innovation in Rare Diseases:
    A recognized expert in familial interstitial lung disease and telomere disorders, his work has led to earlier diagnosis and targeted therapies—critical in fields where few experts exist.

  6. Recognition and Funding:
    He has secured prestigious mobility grants (ERS, Respirology Teachers College)—a marker of trust in his scientific mission and innovation.

🔍 Areas for Improvement:

  • Wider Public Health Translation: While Dr. Borie’s genomic research is exceptional, expanding into real-world health policy implementation could enhance systemic impact.

  • Patient Engagement & Advocacy: Developing patient-oriented tools or registries (e.g., digital apps or platforms for familial lung diseases) may broaden his outreach beyond academia and clinics.

  • Broader Visibility: Although highly cited in professional circles, participation in international keynote talks, editorial leadership, or mainstream health media could elevate his public and professional visibility.

🎓 Education:

Dr. Borie has pursued an extensive and rigorous academic path focused on respiratory and genetic medicine. He obtained his medical degree with specialization in Allergology and Immunopathology in 2006. A year earlier, in 2005, he earned a Master’s degree in Biology and Physiology of Circulation and Respiration. Demonstrating deep interest in genetics, he completed a PhD in Genetics in 2017, contributing significantly to our understanding of genetic underpinnings in pulmonary fibrosis. In 2019, Dr. Borie achieved the prestigious Habilitation à Diriger des Recherches (HDR) from the University of Paris 7, enabling him to supervise doctoral research. His academic background illustrates a powerful integration of clinical expertise and molecular research—providing him with the tools to lead innovative research projects at the intersection of genomics and pulmonology.

🩺 Experience:

Dr. Raphaël Borie has over 15 years of experience in respiratory medicine. From July 2011 to August 2020, he served as a Hospital Practitioner in the Pneumology Department at Bichat Hospital under Professors Aubier and Crestani. Since September 2020, he has been a University Professor Hospital Practitioner in the same department, affiliated with Paris Cité University. He has contributed to patient care, education of medical students and residents, and cutting-edge research. As part of the OrphaLung network, he plays a critical role in advancing diagnostic tools and treatment approaches for rare lung diseases. He is recognized for his collaborative leadership and interdisciplinary contributions across genetics, immunology, and pulmonology. His international collaborations and authorship of over 280 PubMed-indexed publications demonstrate his ongoing commitment to improving patient outcomes through translational research.

🏆 Awards and Honors:

Dr. Borie’s research excellence has been recognized through several prestigious awards and scholarships. In 2017, he received the European Respiratory Society (ERS) Mobility Grant for his work on Identification of Preclinical Markers of Pulmonary Fibrosis, supporting international collaboration and advanced training. The same year, he was also honored with the Respirology Teachers College Mobility Grant, reinforcing his pioneering research on early detection of fibrotic lung disease. His selection for these awards highlights both scientific innovation and dedication to knowledge exchange. His leadership in multi-center studies and involvement in ERS guideline statements further reflect his status as a thought leader in interstitial lung disease. These honors are a testament to his influence in shaping the future of pulmonary genetics and translational respiratory medicine.

🔬 Research Focus:

Dr. Raphaël Borie’s research centers on familial and genetic interstitial lung diseases, particularly the molecular mechanisms behind pulmonary fibrosis, telomere biology, surfactant-related gene variants, and early detection strategies. He works extensively on identifying genetic risk variants (e.g., MUC5B, DSP) and their implications in idiopathic pulmonary fibrosis. Through his participation in the OrphaLung network, he supports genomic screening for hereditary lung disorders and contributes to developing European guidelines. His work bridges genomic medicine and clinical pulmonology, aiming for earlier diagnosis and personalized treatment approaches. He has led and co-authored critical studies on RTEL1 mutations, telomerase complex defects, and familial ILD phenotypes, helping clinicians globally understand the heterogeneity and systemic implications of genetic lung disorders. His collaborative international research ensures his findings are applied in practice to optimize long-term patient care.

📚Publications Top Notes:

  • 🧬 High risk of lung cancer in surfactant-related gene variant carriers – Eur Respir J, 2024

  • 📄 European Respiratory Society Statement on Familial Pulmonary Fibrosis – Eur Respir J, 2022

  • 🧪 Colocalization of Gene Expression and DNA Methylation with Genetic Risk Variants – Am J Respir Crit Care Med, 2022

  • 🧬 RTEL1 mutations and their phenotypic variability – Eur Respir J, 2019

  • 💊 Safety and efficacy of pirfenidone in telomerase mutation carriers – Eur Respir J, 2018

  • 🌐 Diagnosis and follow-up of familial ILD: International survey – BMC Pulmonary Med, 2025

  • 🧬 New 2023 ACR/EULAR APS criteria performance in young patients – Letter, 2025

  • 🫁 A non-resolving cough: a case of familial pulmonary fibrosis – Breathe, 2025

  • 🧬 PFMG2025: Genomic medicine in French healthcare system – Review, 2025

  • 💊 Efficacy of CFTR modulators in ABCA3-deficiency ILD – Open Access, 2025

  • 🧠 Neurological manifestations in VEXAS syndrome – Journal of Neurology, 2025

  • 💉 Real-life use of PEXIVAS reduced-dose regimen in vasculitis – Ann Rheum Dis, 2025

  • 🧫 Recurrent respiratory papillomatosis with lung involvement – Eur Respir J, 2025

  • 🔍 RA-ILD: genetics to clinical overview – Review, 2025

  • 👶 Childhood ILD survivors in adulthood: European study – Eur Respir J, 2025

🧾 Conclusion:

Dr. Raphaël Borie exemplifies the ideal candidate for the Best Researcher Award. His excellence spans across clinical expertise, academic distinction, and international research leadership, especially in genetic and familial interstitial lung diseases—a field with enormous unmet need. His consistent scholarly output, impactful collaborations, and patient-focused studies highlight a unique blend of depth and innovation. While further expansion into public health frameworks and patient engagement tools would be valuable, his profile already reflects a world-class researcher with transformative contributions to pulmonary medicine.

Yuan Ma | Cell Death Pathway | Best Researcher Award

Posted on by sciencefather

Prof Yuan Ma | Cell Death Pathway | Best Researcher Award

Prof Yuan Ma , Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Nanjing Medical University , China

Yuan Ma is a prominent Professor in the Department of Respiratory and Critical Care Medicine at The First Affiliated Hospital of Nanjing Medical University, China. With a medical background and a focus on bronchial asthma, Dr. Ma has made significant contributions to understanding the mechanisms of airway inflammation and remodeling. Through extensive research, he aims to identify novel molecular targets for asthma therapies. His work has been recognized internationally, underscoring his dedication to advancing clinical applications in respiratory medicine.

Publication Profile

Scopus

Strengths for the Award

  1. Extensive Research Experience: Yuan Ma has a robust academic background as a Professor in Respiratory and Critical Care Medicine. His focus on airway inflammation and remodeling in asthma is critical, given the increasing prevalence of respiratory diseases.
  2. Publication Record: With 25 articles in domestic journals and 13 in international journals, his publication record demonstrates both local and global recognition of his work. Notable articles in high-impact journals underscore the significance and relevance of his research.
  3. Innovative Contributions: Ma’s identification of necroptosis-related targets in asthma and the discovery of potential therapeutic compounds indicate significant advancements in the understanding and treatment of asthma, contributing to both academic knowledge and clinical practice.
  4. Grant Funding: Successfully presiding over projects funded by the National Natural Science Foundation of China highlights his ability to secure funding for impactful research, a crucial aspect of a successful research career.
  5. Patents: The issuance of 13 patents illustrates his innovative capacity and the potential for practical applications of his research findings.

Areas for Improvement

  1. Broader Collaborations: While Ma has made significant contributions, fostering collaborations with researchers from diverse fields could enhance interdisciplinary insights and expand the impact of his work.
  2. Professional Memberships: Engaging in professional organizations could provide networking opportunities and enhance visibility in the research community, further strengthening his position.
  3. Public Outreach: Increasing public engagement and dissemination of research findings could elevate awareness about asthma and his innovations, potentially leading to broader societal impact.

Education 

Dr. Yuan Ma obtained his medical degree from a prestigious institution, followed by specialized training in respiratory medicine. He completed his PhD with a focus on airway diseases, where he gained insights into the cellular and molecular mechanisms underlying asthma. Throughout his academic journey, Dr. Ma has cultivated a robust foundation in both clinical practice and research methodology, allowing him to bridge the gap between laboratory findings and patient care. His continuous pursuit of knowledge in respiratory health has led him to engage in various professional development opportunities, enhancing his expertise and contributing to his role as a leader in his field.

Experience 

Dr. Yuan Ma has extensive experience in both clinical and research settings, spanning over a decade. He has presided over significant research projects funded by the National Natural Science Foundation of China, exploring the pathogenesis of asthma and potential therapeutic interventions. His impressive track record includes 25 publications in national journals and 13 in international peer-reviewed journals, showcasing his commitment to advancing respiratory medicine. As a professor, he mentors medical students and residents, fostering the next generation of researchers and clinicians. His collaborative work with national and international peers has enriched his research, contributing to innovative approaches in asthma treatment. Additionally, his contributions to patent development demonstrate his drive to translate research findings into practical applications for better patient outcomes.

Research Focus 

Dr. Yuan Ma’s research primarily focuses on the mechanisms of airway inflammation and remodeling in bronchial asthma. He investigates necroptosis-related biomarkers and their regulatory mechanisms, aiming to identify novel therapeutic targets. His work encompasses exploring molecular compounds that can effectively modulate these targets, enhancing asthma diagnosis and treatment options. Dr. Ma’s innovative studies delve into the role of oxidative stress and MAPK signaling pathways in airway smooth muscle cell behavior. By examining the intricate interactions within the airway microenvironment, he seeks to uncover underlying processes that contribute to asthma exacerbations. His research has significant implications for developing targeted therapies, addressing the unmet needs of asthma patients, and ultimately improving clinical outcomes in respiratory medicine.

Publications Top Notes

  1. Screening, identification and targeted intervention of necroptotic biomarkers of asthma. 📄
  2. Caffeic acid phenethyl ester alleviates asthma by regulating the airway microenvironment via the ROS-responsive MAPK/Akt pathway. 🌱
  3. Morin Attenuates Ovalbumin-induced Airway Inflammation by Modulating Oxidative Stress-responsive MAPK Signaling. 🩺
  4. A case of male primary pulmonary choriocarcinoma. 🦠
  5. Implication of dendritic cells in lung diseases: immunological role of Toll-like receptor 4. 🔬
  6. Glomus tumors of the trachea: 2 case reports and a review of the literature. 📚
  7. Diosmetin prevents TGF-β1-induced epithelial-mesenchymal transition via ROS/MAPK signaling pathways. 🧬
  8. SARS-CoV-2 in the pancreas and the impaired islet function in COVID-19 patients. 🦠
  9. Characteristics of H7N9 avian influenza pneumonia: a retrospective analysis of 17 cases. 📊
  10. Galangin attenuates airway remodeling by inhibiting TGF-β1-mediated ROS generation and MAPK/Akt phosphorylation in asthma. 🌿
  11. Melatonin modulates airway smooth muscle cell phenotype by targeting the STAT3/Akt/GSK-3β pathway in experimental asthma. 🌙
  12. Single-agent Maintenance Therapy for Advanced Non-small Cell Lung Cancer: A Systematic Review and Bayesian Network Meta-analysis. 🧑‍⚕️
  13. Effect of diosmetin on airway remodeling in a murine model of chronic asthma. 🐭

Conclusion

Yuan Ma’s exceptional research contributions in understanding and treating asthma position him as a strong candidate for the Best Researcher Award. His extensive publication record, innovative findings, and successful grant applications reflect a commitment to advancing respiratory medicine. Addressing areas for improvement could further enhance his profile and influence in the field. Overall, Ma’s achievements warrant recognition, and he is well-suited for this prestigious award.

 

 

Shizhu Jin | Basic research on stem stell transplantation for digestive system diseases | Best Scholar Award

Posted on by sciencefather

Prof Dr Shizhu Jin | Basic research on stem stell transplantation for digestive system diseases | Best Scholar Award

Prof Dr Shizhu Jin , The second affiliated hospital of Harbin medical university , China

Shizhu Jin is a distinguished Professor and Chief Physician specializing in Gastroenterology at the Second Affiliated Hospital of Harbin Medical University, China. With extensive experience in both clinical practice and academic research, he has significantly contributed to the field of digestive diseases. His notable achievements include securing 1 national invention patent, 6 utility model patents, and 1 software copyright. Shizhu Jin has published 44 articles in SCI journals with a cumulative impact factor of 209.635 and a total of 1249 citations, reflecting his profound impact on the field. He has been recognized with several accolades, including “Top Ten Teaching Experts of Harbin Medical University” and “Outstanding Medical Aid Expert of Heilongjiang Province.” His leadership extends to various editorial and review roles, highlighting his influence and dedication to advancing gastroenterology and hepatology.

Publication Profile

Scopus

Strengths for the Award

  1. Extensive Research Contributions: Shizhu Jin has made significant contributions to gastroenterology, with 44 articles published in SCI-indexed journals. His research includes high-impact studies with a cumulative impact factor of 209.635 and an H-index of 19, demonstrating both the volume and quality of his work.
  2. Innovative Patents: He holds 1 national invention patent, 6 utility model patents, and 1 software copyright, showcasing his ability to translate research into practical applications.
  3. Leadership in Research Projects: Jin chairs over ten research topics funded by prestigious organizations such as the National Natural Science Foundation of China and the Chinese Medical Foundation, highlighting his leadership and impact on advancing medical science.
  4. Editorial and Review Roles: His involvement as a reviewer and editorial board member for various journals underscores his expertise and influence in the field.
  5. Awards and Recognition: Jin’s accolades, including the “Top Ten Teaching Experts of Harbin Medical University” and “Outstanding Medical Aid Expert of Heilongjiang Province,” reflect his excellence in both research and teaching.

Areas for Improvement

  1. Citation Metrics: Although Jin has a solid citation record, additional high-impact publications could further enhance his research profile. Increasing the citation count of recent publications could bolster his standing in the field.
  2. Collaborations: Expanding collaborations with international researchers and institutions could increase the global impact of his research and open new avenues for innovative projects.
  3. Public Outreach: Greater engagement in public communication of research findings could improve awareness of his work and its significance to broader audiences.

Education 

Shizhu Jin pursued his medical education at Harbin Medical University, where he completed his undergraduate studies in Medicine. He further advanced his expertise with a doctoral degree in Gastroenterology, focusing on innovative research in digestive diseases. His postdoctoral training involved advanced studies and collaborative research, emphasizing the integration of clinical and experimental gastroenterology. Jin’s academic journey has been marked by continuous learning and contribution to the field through rigorous research, resulting in groundbreaking advancements in stem cell therapy and digestive system diseases. His educational background, combined with extensive hands-on experience, has established him as a leading expert and educator in his field, driving both clinical excellence and academic innovation.

Experience 

Professor Shizhu Jin has extensive experience as a leading physician and researcher in Gastroenterology. At the Second Affiliated Hospital of Harbin Medical University, he directs the Ward I of the Department of Gastroenterology, overseeing complex clinical cases and pioneering treatments. His career includes significant contributions to research with over 44 SCI-indexed publications and several high-impact patents. Jin has led numerous research projects funded by prestigious bodies like the National Natural Science Foundation of China and the Chinese Medical Foundation. His professional roles extend to editorial positions in prominent journals and advisory roles in various medical associations. His commitment to advancing medical knowledge and improving patient care through research and innovation underscores his substantial impact on both the clinical and academic aspects of gastroenterology.

Research Focus 

Shizhu Jin’s research primarily focuses on innovative approaches to treating digestive system diseases, including stem cell transplantation and regenerative medicine. His work explores the molecular mechanisms underlying gastrointestinal disorders, aiming to develop novel therapeutic strategies. Jin has made significant contributions to understanding the role of stem cells in treating liver cirrhosis and inflammatory bowel diseases. His research on the signaling pathways involved in disease progression has led to potential breakthroughs in personalized medicine. Jin’s studies on hypoxia-induced factors and tumor microenvironments highlight his commitment to advancing our knowledge of complex digestive diseases. His research not only aims to improve clinical outcomes but also strives to translate scientific discoveries into practical applications for better patient management.

Publications Top Notes

  • GABPA-Mediated Expression of HPN-AS1 Facilitates Cell Apoptosis and Inhibits Cell Proliferation in Hepatocellular Carcinoma by Promoting eIF4A3 Degradation 🧬📉 Turkish Journal of Gastroenterology, 2024, 35(7), pp. 577–586
  • Stimulation by exosomes from hypoxia-preconditioned hair follicle mesenchymal stem cells facilitates mitophagy by inhibiting the PI3K/AKT/mTOR signaling pathway to alleviate ulcerative colitis 🔬🧪 Theranostics, 2024, 14(11), pp. 4278–4296
  • Novel milestones for early esophageal carcinoma: From bench to bed 🏥📚 World Journal of Gastrointestinal Oncology, 2024, 16(4), pp. 1104–1118
  • Development and validation of a blood routine-based extent and severity clinical decision support tool for ulcerative colitis 🩸🔍 Scientific Reports, 2023, 13(1), 21368
  • BMSCs alleviate liver cirrhosis by regulating Fstl1/Wnt/β-Catenin signaling pathway 🧫🩺 Heliyon, 2023, 9(11), e21010
  • Characterization of the metabolic alteration-modulated tumor microenvironment mediated by TP53 mutation and hypoxia 🧪🔬 Computers in Biology and Medicine, 2023, 163, 107078
  • From Phenomenon to Essence: A Newly Involved lncRNA Kcnq1ot1 Protective Mechanism of Bone Marrow Mesenchymal Stromal Cells in Liver Cirrhosis 🧬💉 Advanced Science, 2023, 10(21), 2206758
  • A novel approach to improving colonoscopy learning efficiency through a colonoscope roaming system: randomized controlled trial 🏥📈 PeerJ Computer Science, 2023, 9, e1409
  • Construction of a TTN Mutation-Based Prognostic Model for Evaluating Immune Microenvironment, Cancer Stemness, and Outcomes of Colorectal Cancer Patients 🧬📊 Stem Cells International, 2023, 2023, 6079957
  • Hypoxia-induced factor and its role in liver fibrosis 🔬🩺 PeerJ, 2022, 10, e14299

Conclusion

Shizhu Jin is highly deserving of the Best Researcher Award due to his outstanding research contributions, leadership in high-impact projects, and significant innovations in gastroenterology. His extensive publication record, patent holdings, and prestigious awards reflect a remarkable career dedicated to advancing medical science. Addressing areas for improvement could further elevate his impact and recognition in the global research community.